Arcus Biosciences Inc Asset Resilience Ratio
Arcus Biosciences Inc asset resilience ratio. Arcus Biosciences Inc (RCUS) has an Asset Resilience Ratio of 62.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Arcus Biosciences Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arcus Biosciences Inc (2016–2025)
Asset resilience ratio of Arcus Biosciences Inc from 2016 to 2025. This chart shows how Arcus Biosciences Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Arcus Biosciences Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Arcus Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Arcus Biosciences Inc (RCUS) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $621.00 Million | 62.29% |
| Total Liquid Assets | $621.00 Million | 62.29% |
Asset Resilience Insights
- Very High Liquidity: Arcus Biosciences Inc maintains exceptional liquid asset reserves at 62.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcus Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Arcus Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
Arcus Biosciences Inc Asset Resilience Ratio by Year (2016–2025)
Arcus Biosciences Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Arcus Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.64% | $759.00 Million | $1.14 Billion | -5.36pp |
| 2024-12-31 | 72.00% | $828.00 Million | $1.15 Billion | +14.28pp |
| 2023-12-31 | 57.72% | $632.00 Million | $1.09 Billion | -1.99pp |
| 2022-12-31 | 59.70% | $803.00 Million | $1.34 Billion | +37.63pp |
| 2021-12-31 | 22.07% | $351.39 Million | $1.59 Billion | -49.82pp |
| 2020-12-31 | 71.89% | $555.23 Million | $772.29 Million | +7.73pp |
| 2019-12-31 | 64.17% | $130.33 Million | $203.11 Million | -3.30pp |
| 2018-12-31 | 67.47% | $185.48 Million | $274.93 Million | +26.90pp |
| 2017-12-31 | 40.57% | $77.28 Million | $190.49 Million | +9.82pp |
| 2016-12-31 | 30.75% | $33.74 Million | $109.70 Million | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more